Good news! Biotron successfully completed the development of COVID-19 series detection kit
Coronavirus is a large family of viruses. Known coronaviruses can cause colds and more serious diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The 2019 novel coronavirus, or "2019-nCoV", was discovered due to a Wuhan viral pneumonia case in December 2019. It was named by the World Health Organization on January 12, 2020 and was listed as a public health emergency of international concern ( PHEIC).
The prevention and control of the new coronavirus epidemic is at a critical juncture. The WHO 2019 New Coronavirus Guidelines and China's fifth edition of the "New Coronavirus Infection Pneumonia Diagnosis and Treatment Plan" both emphasize that the upper and lower respiratory tracts should be collected during laboratory examinations of suspected patients. , Blood, and fecal specimens are tested for nCoV through Real-time PCR. The results can be used for rapid identification, diagnosis, or judgment of cure.
Therefore, the development and application of high-quality, fast, accurate, low-cost, easy-to-operate, and versatile diagnostic reagents not only has important practical significance for the current 2019-nCoV epidemic control, but also for long-term monitoring and diversion of overall respiratory tract infections，diagnosis and treatment have long-term guiding significance.
Biotron provides solutions
In the outbreak occasion, Biotron stepped in, using its own technology advantages and accumulation, timely and efficient manner to develop a detection reagent and sample tube for the new coronavirus, contributed their forces to fight the epidemic, demonstrated their play !Biotron provides a multi-dimensional integrated solution around the new coronavirus, including antigen detection, antibody detection, nucleic acid detection and Virus transfer medium.
Biotron's COVID-19 series detection reagent successfully obtained the EU CE access certification on March 21,2020. According to the relevant EU laws and certification procedures, the products comply with The compliance requirements of the "EU Medical Device Directives" have officially obtained the qualifications to enter the EU market, contributing a "China" force to the global common epidemic.
Meanwhile Biotron used the original single-tube multiple probe amplification technology (MPA) to develop a respiratory pathogen nucleic acid joint detection kit based on the RT-PCR platform, which can simultaneously detect 12 respiratory viruses (including the new coronavirus, ORF1ab gene) And 15 bacteria. Because of its extremely high specificity and sensitivity, this technology can screen multiple targets at once, cover common pathogenic pathogens, and it is convenient and fast to detect. It is recognized by customers!
The combined RVP+RBP reagent can realize the “1+1” comprehensive detection mode for common respiratory pathogens. In the combined detection mode, it can detect 2019-nCoV and 32 other respiratory infection pathogens at the same time, which is the most comprehensive detection reagent at home and abroad. (Except for mNGS), it basically covers clinically common pathogens of respiratory tract infections.